Literature DB >> 21334179

The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia.

Isabel Martínez-Gras1, Beatriz G Pérez-Nievas, Borja García-Bueno, José L M Madrigal, Eva Andrés-Esteban, Roberto Rodríguez-Jiménez, Janet Hoenicka, Tomás Palomo, Gabriel Rubio, Juan C Leza.   

Abstract

A number of findings suggest that inflammation plays a role in the pathophysiology of schizophrenia. Taking into account a physiological balance between pro- and anti-inflammatory mediators, we measured the plasma levels of cyclooxygenase-derived mediators and other key pro- and anti-inflammatory transcription factors in peripheral blood mononuclear cells (PBMC). Forty healthy subjects and 46 treated chronic schizophrenic patients with an acutely exacerbated condition who met DSM-IV criteria were included. COX by-products prostaglandin E2 (PGE2) and 15d-prostaglandin J2 (15d-PGJ2) plasma levels were measured by EIA. Peroxisome proliferator-activated receptor gamma (PPARγ) as well as nuclear factor kappaB (NFκB) activity in nuclear extracts from PBMC and expression of its inhibitory subunit IκBα in cytosolic extracts were determined using ELISA-based kits. Schizophrenic patients showed higher plasma levels of pro-inflammatory PGE2 than age-matched controls (p=0.043). On the contrary, levels of anti-inflammatory 15-d-PGJ2 were lower (p=0.004), correlating with a lower expression of its nuclear target, PPARγ in nuclear extracts from PBMC (p=0.001). Although no changes in NFκB activity were observed between patients and healthy controls, the expression of its inhibitory protein IκBα was lower in the patients compared to the controls (p=0.027). These findings suggest that schizophrenia is associated with a systemic imbalance in the plasma levels of pro-inflammatory/anti-inflammatory prostaglandins in favor of the former. Furthermore, the expression and activity of anti-inflammatory PPARγ are diminished in PBMC, which indicates a state of inflammation and blunted anti-inflammatory counterbalancing mechanisms at systemic level in these patients.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21334179     DOI: 10.1016/j.schres.2011.01.018

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  28 in total

Review 1.  Inflammation and the two-hit hypothesis of schizophrenia.

Authors:  Keith A Feigenson; Alex W Kusnecov; Steven M Silverstein
Journal:  Neurosci Biobehav Rev       Date:  2013-11-15       Impact factor: 8.989

2.  Autophagy Modulation in Disease Therapy: Where Do We Stand?

Authors:  Michael P Nelson; John J Shacka
Journal:  Curr Pathobiol Rep       Date:  2013-12-01

3.  Glucocorticoid receptor alpha translational isoforms as mediators of early adversities and negative emotional states.

Authors:  Miroslav Adzic; Emilija Glavonic; Milica J Nesic; Minja Milosavljevic; Marina Mihaljevic; Zorica Petrovic; Zorana Pavlovic; Zeljka Brkic; Ester Francija; Ivan Soldatovic; Milos Mitic; Jelena Radulovic; Nadja P Maric
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2018-12-21       Impact factor: 5.067

4.  Differences in the regulation of inflammatory pathways in adolescent- and adult-onset first-episode psychosis.

Authors:  C Moreno; M Parellada; K S MacDowell; B García-Bueno; B Cabrera; A González-Pinto; P Saiz; A Lobo; R Rodriguez-Jimenez; E Berrocoso; M Bernardo; J C Leza
Journal:  Eur Child Adolesc Psychiatry       Date:  2019-03-06       Impact factor: 4.785

5.  Metabolic and inflammatory genes in schizophrenia.

Authors:  Kayla A Chase; Cherise Rosen; Hannah Gin; Olivia Bjorkquist; Benjamin Feiner; Robert Marvin; Sean Conrin; Rajiv P Sharma
Journal:  Psychiatry Res       Date:  2014-11-13       Impact factor: 3.222

6.  The Possible Role of the Angiotensin System in the Pathophysiology of Schizophrenia: Implications for Pharmacotherapy.

Authors:  SeungJu Jackie Oh; Xiaoduo Fan
Journal:  CNS Drugs       Date:  2019-06       Impact factor: 5.749

7.  Lipidomics profile of a NAPE-PLD KO mouse provides evidence of a broader role of this enzyme in lipid metabolism in the brain.

Authors:  Emma Leishman; Ken Mackie; Serge Luquet; Heather B Bradshaw
Journal:  Biochim Biophys Acta       Date:  2016-03-05

8.  Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia.

Authors:  Borja García-Bueno; Miquel Bioque; Karina S Mac-Dowell; M Fe Barcones; Monica Martínez-Cengotitabengoa; Laura Pina-Camacho; Roberto Rodríguez-Jiménez; Pilar A Sáiz; Carmen Castro; Amalia Lafuente; Javier Santabárbara; Ana González-Pinto; Mara Parellada; Gabriel Rubio; M Paz García-Portilla; Juan A Micó; Miguel Bernardo; Juan C Leza
Journal:  Schizophr Bull       Date:  2013-03-13       Impact factor: 9.306

9.  RETRACTED: Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients.

Authors:  Jagadeesh Sridhara Rao; Hyung-Wook Kim; Gaylia Jean Harry; Stanley Isaac Rapoport; Edmund Arthur Reese
Journal:  Schizophr Res       Date:  2013-04-06       Impact factor: 4.939

10.  Molecular profiles of parvalbumin-immunoreactive neurons in the superior temporal cortex in schizophrenia.

Authors:  Charmaine Y Pietersen; Sarah A Mauney; Susie S Kim; Eleonora Passeri; Maribel P Lim; Robert J Rooney; Jill M Goldstein; Tracey L Petreyshen; Larry J Seidman; Martha E Shenton; Robert W Mccarley; Kai-C Sonntag; Tsung-Ung W Woo
Journal:  J Neurogenet       Date:  2014-03-17       Impact factor: 1.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.